aspirin has been researched along with 7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Backman, V; Carolan, PJ; Chan, AT; Chin, SM; Chung, DC; Colizzo, FP; Drew, DA; Flagg, M; Freedman, M; Gala, M; Garber, JJ; Gilpin, KK; Huttenhower, C; Kedrin, D; Khalili, H; Kwon, DS; Markowitz, SD; Milne, GL; Nishioka, NS; Parziale, M; Pond, E; Rawlings, CA; Richter, JM; Roy, HK; Schuck, MM; Staller, K; Stewart, K; Wang, M | 1 |
1 trial(s) available for aspirin and 7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid
| Article | Year |
|---|---|
ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial.
Topics: Adenoma; Adolescent; Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Aspirin; Biomarkers, Tumor; Boston; Carcinoma; Clinical Protocols; Colorectal Neoplasms; Cytokines; Disease Progression; Double-Blind Method; Female; Humans; Inflammation Mediators; Male; Middle Aged; Prospective Studies; Prostaglandins; Protective Factors; Research Design; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2017 |